AG
AIMT

Advisor Group’s Aimmune Therapeutics AIMT Stock Holding History

Advisor Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$101K Buy
3,029
+245
+9% +$6.85K ﹤0.01% 2936
2019
Q3 		$58K Buy
2,784
+1,349
+94% +$27.5K ﹤0.01% 3285
2019
Q2 		$29K Sell
1,435
-2
-0.1% -$41 ﹤0.01% 3740
2019
Q1 		$33K Sell
1,437
-300
-17% -$7.06K ﹤0.01% 3677
2018
Q4 		$42K Buy
1,737
+796
+85% +$20.6K ﹤0.01% 3310
2018
Q3 		$26K Buy
941
+100
+12% +$2.83K ﹤0.01% 3739
2018
Q2 		$22K Buy
841
+261
+45% +$7.99K ﹤0.01% 3668
2018
Q1 		$19K Buy
580
+30
+5% +$1.06K ﹤0.01% 3725
2017
Q4 		$21K Sell
550
-41
-7% -$1.32K ﹤0.01% 3698
2017
Q3 		$14K Buy
591
+79
+15% +$1.7K ﹤0.01% 3789
2017
Q2 		$11K Sell
512
-25
-5% -$477 ﹤0.01% 3892
2017
Q1 		$12K Sell
537
-10
-2% -$205 ﹤0.01% 3695
2016
Q4 		$11K Hold
547
– – ﹤0.01% 3589
2016
Q3 		$8K Buy
547
+50
+10% +$675 ﹤0.01% 3713
2016
Q2 		$5K Buy
+497
New +$6.75K ﹤0.01% 3812

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Advisor Group's AIMT Position: Q4 2019 in Review

Advisor Group increased its Aimmune Therapeutics (AIMT) stake by 8.8% in Q4 2019, buying an estimated $6.85K and bringing the position to 3,029 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Advisor Group first reported a position in AIMT in Q2 2016 and has held it in 15 quarters since. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Advisor Group held 3,029 shares of Aimmune Therapeutics worth $101K as of Q4 2019.
  • Advisor Group bought 245 Aimmune Therapeutics shares in Q4 2019, an estimated $6.85K.
  • Aimmune Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2936 holding.
  • Advisor Group first reported a position in Aimmune Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.